Kuril'skaia T E, Tarabrin A L, Kuznetsova E E, Leont'eva V G, Chizhova E A, Misharina N P, Kuznetsov N P, Runovich A A
Ter Arkh. 1997;69(2):55-8.
The study included 30 IHD patients with primary hypercholesterolemia (22 males and 8 females). 18 and 12 patients have received a single daily dose of fluvastatin 20 and 40 mg, respectively, in the evening for 12 weeks. The drug effect was assessed by changes in the clinical status, lipid spectrum, transport-metabolic and absorption-secretory functions of the liver. IHD patients with hypercholesterolemia were found to have dysfunction of the hepatobiliary system. Fluvastatin treatment reduced the level of total cholesterol (Ch), LDLP Ch, triglycerides. HDLP Ch levels remained unchanged. Atherogenic lipoproteins aggregation diminished. Positive changes occurred in hepatic metabolism: bilirubin concentrations lowered, serum albumin went up, absorption-secretory function of hepatocytes normalized, hepatic mono-oxidase system activated. Fluvastatin-related hepatic damage was not reported in the course of 12-month follow-up.
该研究纳入了30例原发性高胆固醇血症的缺血性心脏病（IHD）患者（22例男性和8例女性）。18例和12例患者分别于每晚接受20毫克和40毫克氟伐他汀的单日剂量治疗，为期12周。通过临床状态、血脂谱、肝脏的转运代谢及吸收分泌功能的变化来评估药物疗效。发现患有高胆固醇血症的IHD患者存在肝胆系统功能障碍。氟伐他汀治疗降低了总胆固醇（Ch）、低密度脂蛋白胆固醇（LDLP Ch）、甘油三酯的水平。高密度脂蛋白胆固醇（HDLP Ch）水平保持不变。致动脉粥样硬化脂蛋白聚集减少。肝脏代谢出现积极变化：胆红素浓度降低，血清白蛋白升高，肝细胞的吸收分泌功能正常化，肝脏单氧化酶系统激活。在12个月的随访过程中未报告与氟伐他汀相关的肝损伤。
